Xtx Topco LTD Relay Therapeutics, Inc. Transaction History

Xtx Topco LTD

$2.23 Billion
Q2 2025

A detailed history of Xtx Topco LTD transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 241,230 shares of RLAY stock, worth $1.47 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

241,230

Previous 79,913 201.87%

Holding current value

$1.47 Million

Previous $209,000 299.04%

% of portfolio

0.04%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$2.0 - $3.49 $322,634 - $562,996	161,317 Added 201.87%	241,230 $834,000
Q1 2025 May 07, 2025	BUY	$2.62 - $4.92 $52,821 - $99,192	20,161 Added 33.74%	79,913 $209,000
Q4 2024 Feb 13, 2025	BUY	$4.12 - $6.8 $51,421 - $84,870	12,481 Added 26.4%	59,752 $246,000
Q3 2024 Nov 14, 2024	BUY	$6.23 - $9.51 $64,237 - $98,057	10,311 Added 27.9%	47,271 $334,000
Q2 2024 Aug 12, 2024	BUY	$5.9 - $8.02 $3,711 - $5,044	629 Added 1.73%	36,960 $240,000
Q1 2024 May 13, 2024	BUY	$7.5 - $12.07 $189,465 - $304,912	25,262 Added 228.22%	36,331 $301,000
Q4 2023 Feb 13, 2024	SELL	$6.01 - $11.48 $71,290 - $136,175	-11,862 Reduced 51.73%	11,069 $121,000
Q3 2023 Nov 13, 2023	BUY	$8.24 - $12.97 $42,979 - $67,651	5,216 Added 29.44%	22,931 $192,000
Q2 2023 Aug 14, 2023	BUY	$9.99 - $18.27 $176,972 - $323,653	17,715 New	17,715 $222,000
Q4 2022 Feb 14, 2023	BUY	$14.16 - $24.02 $181,177 - $307,335	12,795 New	12,795 $191,000
Q1 2022 May 13, 2022	SELL	$20.26 - $32.36 $145,345 - $232,150	-7,174 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$26.0 - $37.03 $186,524 - $265,653	7,174 New	7,174 $220,000

Others Institutions Holding RLAY

# of Institutions

214

Shares Held

173M

Call Options Held

Put Options Held

36.1K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $735M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account